invasive fungal infection prophylaxis
Infectious disease · 2008–2014
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| voriconazole Prophylaxis of invasive fungal infections in patients at high risk, including those with acute myeloid leukaemia, high-risk myelodysplastic syndrome, graft… | Mar 2014 | Recommended with restriction | none received |
| posaconazole Prophylaxis of invasive fungal infections (yeasts and moulds) in patients 13 years or older at high risk, including those with prolonged neutropenia or severe… | Mar 2008 | Recommended with restriction | no section in document |
What the PBS pays
$10M in government benefit over 2024–25, across 23,635 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| posaconazole | $9M |
| voriconazole | $1.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.